10:48 AM EDT, 03/20/2024 (MT Newswires) -- Scilex ( SCLX ) said Wednesday it and its subsidiary Scilex Pharmaceuticals reached a settlement with Takeda Pharmaceuticals USA and its parent Takeda Pharmaceutical ( TAK ) to resolve a patent dispute over Scilex's ( SCLX ) gout treatment Gloperba.

Takeda filed a Paragraph IV patent infringement lawsuit against Scilex ( SCLX ) in November 2023 after Scilex ( SCLX ) filed a supplemental new drug application with the US Food and Drug Administration to expand the label for Gloperba, its liquid colchicine product.

As part of the settlement, Scilex ( SCLX ) said it gained a non-exclusive license to certain Takeda patents. Terms were not disclosed.

The agreement requires approval by the district court and by both the Federal Trade Commission and the US Department of Justice, as mandated for Paragraph IV patent case settlements, the company said.

Neither Scilex ( SCLX ) nor Takeda immediately responded to MT Newswires' requests for comment.

Scilex ( SCLX ) shares were up 2.2% while Takeda shares were marginally advancing in recent Wednesday trading.

Price: 1.38, Change: +0.03, Percent Change: +2.22